C83.5A
Lymphoblastic (diffuse) lymphoma, in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
Lymphoblastic (diffuse) lymphoma is a type of non-Hodgkin lymphoma characterized by the abnormal growth of lymphoblasts, which are immature lymphocytes. When it reaches a stage where signs of active disease are no longer present, it is described as being in remission. This condition, coded as C83.5A in the ICD-10 classification, indicates that the lymphoma has responded to treatment and is currently not active, though careful monitoring remains essential. Remission can be temporary or long-lasting, depending on various factors related to the individual’s health and treatment outcomes.
Causes & Symptoms
Clinical Causes: Genetic mutations that cause abnormal lymphocyte growth Exposure to certain chemicals or radiation Immune system deficiencies or disorders Infections that may trigger lymphoid cell changes Chemotherapy or immunotherapy treatments that initially treat the disease
Key Symptoms: Swollen lymph nodes, often painless, in neck, armpits, or groin Unexplained weight loss Fever that persists over a few days or weeks Night sweats Fatigue or weakness Frequent infections due to weakened immune response Persistent cough or chest pain, if lymph nodes in the mediastinum are involved
Diagnostic & Treatment
Diagnosis Path: Diagnosis of lymphoblastic lymphoma in remission involves a combination of clinical assessments, imaging tests, and laboratory procedures. Common methods include:
Treatment Protocols: While a lymphoma in remission indicates that active disease is not currently present, ongoing management is vital to sustain remission and monitor potential relapse. Standard approaches may include:
Clinical Advice & FAQs
Billing Guidance
Is C83.5A a billable ICD-10 code?
Yes, C83.5A is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C83.5A?
Clinical documentation must specify the nature of Lymphoblastic (diffuse) lymphoma, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference